TLDR
- Capricor Therapeutics (CAPR) shares climbed following the presentation of extended Phase 3 trial data for deramiocel, a treatment targeting Duchenne muscular dystrophy, at the World Muscle Society congress in Hiroshima.
- Of 106 participants enrolled in the HOPE-3 study, 82 completed the 24-month evaluation period, with findings incorporated into the company’s regulatory submission to the FDA.
- The drug successfully achieved its 12-month primary goal, demonstrating a 54% reduction in upper-limb function decline compared to placebo.
- A July FDA advisory panel voted 9-3 against endorsing the treatment’s cardiomyopathy benefits, though panelists expressed greater support for the upper-limb functional outcomes.
- The regulatory agency’s final verdict is expected by the PDUFA target date of November 22.
Capricor Therapeutics stock gained ground during after-hours trading Tuesday following the company’s disclosure of extended trial results for deramiocel, its investigational Duchenne muscular dystrophy therapy. The information emerged through ePosters published for the World Muscle Society’s 31st Annual Congress taking place in Hiroshima, Japan.
Capricor Therapeutics, Inc., CAPR
The release’s timing carries particular significance. With an FDA ruling on deramiocel expected by November 22, this isn’t merely a routine scientific update. The findings represent a substantial amendment to the company’s Biologics License Application, indicating that federal regulators are currently reviewing this information.
The presentation encompasses participants from the Phase 3 HOPE-3 study along with its open-label extension phase. Among the initial 106 randomized participants, 82 reached the two-year evaluation point. This cohort included 40 individuals who received deramiocel from trial initiation and 42 who initially received placebo.
Understanding the Delayed-Start Trial Architecture
Researchers employed a delayed-start framework for this investigation. During the initial 12 months, participants received either deramiocel or placebo. Subsequently, qualifying participants could transition into the open-label extension phase and begin receiving deramiocel irrespective of their initial assignment.
This methodology enables scientists to evaluate early treatment initiation against delayed intervention. It addresses whether prompt treatment produces sustained advantages and whether participants switching from placebo experience any shift in disease progression patterns. The poster additionally compares two-year outcomes against natural-history datasets, providing context for typical disease advancement.
These extended findings expand upon the initial 12-month HOPE-3 outcomes. That study achieved its primary objective, demonstrating a 54% reduction in upper-limb function decline measured by the Performance of the Upper Limb 2.0 assessment versus placebo. The statistical significance registered at p=0.03. These results appeared in The Lancet during July.
Navigating Conflicting FDA Feedback
The regulatory pathway has encountered challenges. During July, an FDA advisory committee determined by a 9-3 margin that available evidence inadequately demonstrated deramiocel’s efficacy for treating cardiomyopathy specifically in Duchenne patients.
That determination was narrowly focused. It exclusively evaluated cardiomyopathy benefits rather than the treatment’s comprehensive risk-benefit profile, and committee participants expressed more favorable perspectives when discussing HOPE-3 upper-limb functional data. The FDA maintains discretion to decide independently of advisory recommendations.
Capricor is simultaneously utilizing the WMS congress platform to present exploratory research. A Wednesday poster describes the company’s StealthX exosome technology, designed to transport micro-dystrophin as a repeatedly administrable Duchenne intervention. Another Friday poster examines a comparable delivery mechanism targeting Pompe disease.
Both initiatives remain in preclinical development, positioning them several years from potential regulatory consideration. They offer stakeholders insight into Capricor’s research portfolio extending beyond deramiocel.
Additional presentations are scheduled throughout the week. Craig McDonald from UC Davis will deliver an oral presentation on October 3 examining HOPE-3 evidence addressing both skeletal-muscle and cardiac outcomes.
Capricor has indicated it will publish presentation materials and posters on its corporate website following each session. The biotech company’s market capitalization approximates $498 million, and it presently lacks product revenue, depending instead on financing mechanisms and partnerships such as its Japanese collaboration with Nippon Shinyaku.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
